A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain
Randomised controlled trialHumans
- Design
- Randomised controlled trial
- Subjects
- 70 adults with nerve pain related to diabetes randomised at one centre. 66 completed.
- Dose used in the study
- 600 mg a day of Levagen+
- Duration
- 8 weeks
- What was measured
- Pain severity and interference on the BPI-DPN questionnaire, and pain characteristics on the NPSI. Sleep, mood, blood markers and safety.
What the authors reported
The authors reported lower total pain, pain interference and NPSI scores than placebo from week 2 onward (P ≤ 0.001). They also reported better sleep and mood scores and lower IL-6 and CRP. Adverse events were mild and short, and none led to withdrawal.
Limits of this study
One centre, 70 participants and 8 weeks. Most participants had type 2 diabetes, and blood sugar control varied. The authors called for larger studies. The funding statement was not visible on the page checked.
Source
doi:10.1007/s10787-022-01033-8
Entry checked against the article page at the publisher (Springer) on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.